These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31072670)

  • 1. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
    Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
    Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
    Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
    Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
    Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
    Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors: Impact of Lymph Node Positivity on Survival.
    Jutric Z; Grendar J; Hoen HM; Cho SW; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    Pancreas; 2017 Aug; 46(7):898-903. PubMed ID: 28697130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors.
    Zaidi MY; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Makris E; Rocha F; Crown A; Idrees K; Marincola Smith P; Nathan H; Beems M; Abbott D; Barrett JR; Fields RC; Davidson J; Cardona K; Maithel SK
    JAMA Surg; 2019 Feb; 154(2):134-140. PubMed ID: 30383112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
    Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
    Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study.
    Perinel J; Nappo G; Zerbi A; Heidsma CM; Nieveen van Dijkum EJM; Han HS; Yoon YS; Satoi S; Demir IE; Friess H; Vashist Y; Izbicki J; Muller AC; Gloor B; Sandini M; Gianotti L; Subtil F; Adham M
    Surgery; 2022 Sep; 172(3):975-981. PubMed ID: 35623953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors.
    Zhang Z; Liu M; Ji S; Luo G; Xu W; Liu W; Hu Q; Sun Q; Ye Z; Qin Y; Fan G; Yu X; Xu X
    Pancreas; 2020 Mar; 49(3):381-386. PubMed ID: 32132507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
    Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
    Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors.
    Gaitanidis A; Patel D; Nilubol N; Tirosh A; Kebebew E
    J Clin Endocrinol Metab; 2018 Jan; 103(1):187-195. PubMed ID: 29069375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
    Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
    Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.